Depression Clinical Trial
Official title:
Pharmacogenomics of Antidepressant Response in Children and Adolescents
This study will identify variations in genes that may be involved in the development of suicidal events or certain behaviors in youth who are exposed to antidepressant medications.
Pharmacogenomics of Antidepressant Response in Children and Adolescents (PARCA) is a
sub-study of the Antidepressant Safety in Kids (ASK) study. PARCA and ASK are part of the
Child and Adolescent Psychiatry Trials Network (CAPTN).
Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake
inhibitor (SNRI) medications are prescribed to approximately 2 to 3% of American children.
Evidence suggests that these medications are beneficial for treating obsessive-compulsive
disorder (OCD), anxiety disorders, and major depressive disorder. Following hearings in
February and September of 2004, the FDA mandated Black Box warnings for all antidepressants,
cautioning prescribers about the risk of treatment-emergent suicidal tendency in children
and adolescents treated with these drugs. Although prescribing waned somewhat following the
warning, many children continue to receive SSRIs and SNRIs for a variety of conditions that
do not have empirically validated alternative treatments. Therefore, there is a pressing
need to clearly understand the safety, tolerability, and effectiveness of SSRIs and SNRIs in
children and adolescents. This study will identify variations in differentially expressed
genes that may be involved in the development of suicidal events and certain behaviors in
youth exposed to antidepressant medications.
Specific aims of the study include the following:
1. To establish a genetic susceptibility database by creating a DNA repository of 120
patients with a prospectively identified "Suicidal Event" and 360 closely matched
antidepressant-tolerant controls, including rigorous phenotypic characterization of
these patients;
2. To establish a genetic susceptibility database by creating a DNA repository of 120
patients with prospectively identified "Behavioral Activation" and 360 closely matched
antidepressant-tolerant controls, including rigorous phenotypic characterization of
these patients;
3. To establish a genetic susceptibility database by creating a DNA repository of 120
patients with prospectively identified co-occurring "Suicidal Event and Behavioral
Activation" and 360 closely matched antidepressant-tolerant controls, including
rigorous phenotypic characterization of these patients;
4. To identify genetic polymorphisms responsible for the development of "Suicidal Events"
using a candidate gene approach, including biosynthetic pathways, metabolizing enzymes,
transporters, ion channels, and receptors;
5. To identify genetic polymorphisms responsible for the development of "Behavioral
Activation" using a candidate gene approach, including biosynthetic pathways,
metabolizing enzymes, transporters, ion channels, and receptors;
6. To use these data along with data from the parent study, ASK, to better understand the
relationship between "Suicidal Events" and "Behavioral Activation."
Participants will include participants of the ASK study who want to participate in the PARCA
study. Participants will use a self-collection kit to provide a saliva sample. The saliva
sample will be mailed to the study center for DNA analysis. There will be no study visits.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A |